Breast cancer accounts for 31% of all cancers diagnosed in Indian women, making it the leading type of cancer. This serious disease must be treated at an early stage for the best outcomes. Our blog breaks down the breast cancer t..
Mashi 2023: I-Abemaciclib (Verzenio, Eli Lilly and Company) kanye nokwelashwa kwe-endocrine (tamoxifen noma i-aromatase inhibitor) kugunyazwe i-Food and Drug Administration (FDA) ukuze kusetshenziswe i-adjuvant yeziguli ezikhulile ezine-.
Feb 2023: Enhertu (trastuzumab deruxtecan) from AstraZeneca and Daiichi Sankyo has been approved as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ..
Feb 2023: U-Hamsa Nandini, owatholakala ene-Grade III Invasive Carcinoma (Umdlavuza Webele) ngo-2021, ubuyekeze abalandeli bakhe be-Instagram ngesimo sakhe sezempilo. Lo mlingisi oseke wabonakala kumafilimu eTelugu afana noMirchi noLege.
Feb 2023: The Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for people with hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cance..
In February 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for women or men over 50 who have advanced or metastatic breast cancer and are ER-positive, HER2-negative, and h..
Ngo-Ephreli 2022: Iziguli zabantu abadala ezinomdlavuza webele we-HER2 ongenakunqandeka noma one-metastatic ezithole uhlobo lwangaphambili olusekelwe ku-HER2 olusekelwe kuhlelo lwe-metastatic, noma ku-neoadjuvant noma i-adjuvant setting futhi luye lwakhula.
Mashi 2022: I-Food and Drug Administration igunyaze i-olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) yokwelapha i-adjuvant yeziguli ezikhulile ezinegciwane elisusayo noma elisolwa ngokususa i-BRCA-mutated (gBRCAm) h.
Okthoba 2021: Ukuphathwa Kwezokudla Nezidakamizwa kugunyaze i-abemaciclib (i-Verzenio, i-Eli Lilly neNkampani) ngokuhlanganiswa nokwelashwa kwe-endocrine (tamoxifen noma i-aromatase inhibitor) yokwelashwa kwe-adjuvant yeziguli zabantu abadala ezine-ho..
Agasti 2021: IPembrolizumab (Keytruda, Merck) yamukelwa yi-FDA ngomdlavuza webele onobungozi obukhulu, wesigaba sokuqala (i-TNBC) njengokwelashwa kwe-neoadjuvant kuhlangene ne-chemotherapy, futhi kamuva njenge-ejenti eyodwa njenge-adjuv ..